Result of AGM

Summary by AI ^BETAClose X

ProBiotix Health plc announced that all resolutions were duly passed at its Annual General Meeting held on June 23, 2026. The company, which develops probiotics for cardiometabolic health, will make the full voting results available on its website. This announcement contains information considered inside information prior to its disclosure.

Disclaimer*

Probiotix Health PLC

23 June 2026

ProBiotix Health plc

("ProBiotix" or the "Company")

Result of AGM

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce that at the AGM held earlier today, all resolutions were duly passed.

The full voting results will be available on the website in due course here: www.probiotixhealth-ir.com

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

ProBiotix Health plc	https://probiotixhealth-ir.com/
	investors@probiotixhealth.com
Steen Andersen, Chief Executive Officer Miles Nolan, Investor Relations

AlbR Capital Limited Aquis Corporate Adviser and Broker	Tel: 020 7469 0930
David Coffman Dan Harris

Notes to Editors:

ProBiotix Health is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.

The Company has a unique approach; discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END